这是描述信息

Explore Hongqi pharmaceutical

Since 1980

More than 30 years of unremitting efforts

Focus on

Anti tuberculosis drugs

Hongqi pharmaceutical "no longer bothered by tuberculosis"

We should enrich first-line anti tuberculosis drugs, build second-line multi drug resistant anti tuberculosis drugs, and make efforts to benefit global TB patients based on domestic and global perspectives.

In 2019, R & D investment accounts for 7.65% of the company's sales revenue.

Hongqi pharmaceutical has successively introduced rifampicin freeze-dried powder injection for injection and isoniazid injection, and developed a domestic class I new drug PA-824, bringing more drug choices for tuberculosis patients.

Hongqi pharmaceutical builds a new tuberculosis drug production line according to who PQ standard

We have built a professional team for the promotion and service of anti tuberculosis drugs in China, strengthened hospital promotion and channel coverage, and improved academic promotion ability and brand building.

Join us

The sky is high and the sea is wide

8

Recruitment position

这是描述信息

In 2010, Hongqi pharmaceutical became a member of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical", stock code: 600196. Sh, 02196. HK). With the mission of "no longer suffering from tuberculosis" and the vision of "creating an international first-class anti tuberculosis drug pharmaceutical enterprise", Hongqi Pharmaceutical Co., Ltd. enriches first-line anti tuberculosis drugs, constructs second-line multi drug resistant anti tuberculosis drugs, and is committed to benefiting global TB patients based on domestic and global perspectives.

Copyright hongqipharma.com All rights reserved     Powered by:300.cn Shenyang    辽icp备12005917号    (辽)-非经营性-2018-0012 

Add:Shenyang Hunnan New District envelope 6th Street    Tel:024-23786268-8012  Fax:024-23786263